Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
The purpose of this study is to see if a radioactive substance called 18F-Fluorodeoxyglucose (18F- FDG), injected into the cervix during a PET/CT scan done before surgery can show us more clearly which lymph nodes in the pelvis (the area near your uterus and cervix) contain cancer.
Inclusion Criteria:
The study population will include women with stage IB1 cervical cancer (any histologic subtype) deemed eligible for surgery, and women with a clinical stage I high-grade endometrial cancer planning to undergo surgical staging. High grade is defined by the following:
Age ≥18 years
Hemoglobin ≥10 g/dL
Plasma albumin ≥3 g/dL
GOG performance status ≤2
Plasma glucose ≤200 mg/dL
Plasma creatinine ≤1.6
Well-controlled hypertension
Medical clearance for surgery and considered an appropriate surgical candidate
Negative serum pregnancy test, if of child-bearing potential
If, based on surgeon's assessment, the patient is recommended to undergo surgical staging for histologically confirmed endometrial cancer or if IB1 cervical cancer is deemed eligible for surgical treatment of disease
Participation in other research protocols does not exclude a patient from participation in this study
Exclusion Criteria:
For Stage 2: